Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.

Literature DB >> 27272045

Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden.

T I Verhoef^1,2, W K Redekop³, S Langenskiold^4,5, F Kamali⁶, M Wadelius⁷, G Burnside⁸, A-H Maitland-van der Zee², D A Hughes⁹, M Pirmohamed⁸.

Abstract

We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden.

Entities: Chemical

Mesh：

Substances：

Year: 2016 PMID： 27272045 DOI： 10.1038/tpj.2016.41

Source DB: PubMed Journal: Pharmacogenomics J ISSN： 1470-269X Impact factor: 3.550

36 in total

1. Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors: P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal: Clin Pharmacol Ther Date: 2010-04-07 Impact factor: 6.875

2. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.

Authors: P J Avery; A Jorgensen; A K Hamberg; M Wadelius; M Pirmohamed; F Kamali
Journal: Clin Pharmacol Ther Date: 2011-09-28 Impact factor: 6.875

3. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.

Authors: Lisa M Meckley; James M Gudgeon; Jeffrey L Anderson; Marc S Williams; David L Veenstra
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

4. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.

Authors: Harriette G C Van Spall; Lars Wallentin; Salim Yusuf; John W Eikelboom; Robby Nieuwlaat; Sean Yang; Conrad Kabali; Paul A Reilly; Michael D Ezekowitz; Stuart J Connolly
Journal: Circulation Date: 2012-10-01 Impact factor: 29.690

5. A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors: Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal: N Engl J Med Date: 2013-11-19 Impact factor: 91.245

Review 6. Stroke prevention in atrial fibrillation: a systematic review.

Authors: Gregory Y H Lip; Deirdre A Lane
Journal: JAMA Date: 2015-05-19 Impact factor: 56.272

7. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors: Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal: Ann Intern Med Date: 2007-06-19 Impact factor: 25.391

8. The largest prospective warfarin-treated cohort supports genetic forecasting.

Authors: Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas
Journal: Blood Date: 2008-06-23 Impact factor: 22.113

9. A method to determine the optimal intensity of oral anticoagulant therapy.

Authors: F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal: Thromb Haemost Date: 1993-03-01 Impact factor: 5.249

10. Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation.

Authors: J Pink; M Pirmohamed; S Lane; D A Hughes
Journal: Clin Pharmacol Ther Date: 2013-09-23 Impact factor: 6.875

9 in total

Review 1. An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review.

Authors: Antony Martin; Jennifer Downing; Michelle Maden; Nigel Fleeman; Ana Alfirevic; Alan Haycox; Munir Pirmohamed
Journal: Pharmacogenomics Date: 2017-11-02 Impact factor: 2.533

Review 2. Exploring the Use of Molecular Biomarkers for Precision Medicine in Age-Related Macular Degeneration.

Authors: Laura Lorés-Motta; Eiko K de Jong; Anneke I den Hollander
Journal: Mol Diagn Ther Date: 2018-06 Impact factor: 4.074

Review 3. Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine.

Authors: Kipp W Johnson; Khader Shameer; Benjamin S Glicksberg; Ben Readhead; Partho P Sengupta; Johan L M Björkegren; Jason C Kovacic; Joel T Dudley
Journal: JACC Basic Transl Sci Date: 2017-06-26

4. Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study.

Authors: Andrea L Jorgensen; Clare Prince; Gail Fitzgerald; Anita Hanson; Jennifer Downing; Julia Reynolds; J Eunice Zhang; Ana Alfirevic; Munir Pirmohamed
Journal: BMC Med Date: 2019-04-08 Impact factor: 8.775

5. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.

Authors: Ye Zhu; Kristi M Swanson; Ricardo L Rojas; Zhen Wang; Jennifer L St Sauver; Sue L Visscher; Larry J Prokop; Suzette J Bielinski; Liewei Wang; Richard Weinshilboum; Bijan J Borah
Journal: Genet Med Date: 2019-10-08 Impact factor: 8.822

6. Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation.

Authors: Saowalak Turongkaravee; Jiraphun Jittikoon; Onwipa Rochanathimoke; Kathleen Boyd; Olivia Wu; Usa Chaikledkaew
Journal: BMC Health Serv Res Date: 2021-10-02 Impact factor: 2.655